Characterization of botulinum neurotoxin type A subtypes by immunocapture enrichment and liquid chromatography–tandem mass spectrometry by Morineaux, Valérie et al.
For Peer Review
 1
CHARACTERIZATION OF BOTULINUM NEUROTOXIN TYPE A 
SUBTYPES BY IMMUNOCAPTURE ENRICHMENT AND LIQUID 
CHROMATOGRAPHY TANDEM-MASS SPECTROMETRY 
 
Valérie MORINEAUX1,2, Christelle MAZUET2, Didier HILAIRE1, Julien ENCHE1, Michel 
R. POPOFF2 
 
 
1Direction Générale de l'Armement, DGA Maîtrise NRBC, Vert-le-Petit, France 
 
2Institut Pasteur, Unité des Bactéries anaérobies et Toxines, Paris, France 
 
 
 
 
Key words: Botulinum neurotoxin, Clostridium botulinum, subtyping, mass spectrometry 
Page 1 of 24 Analytical & Bioanalytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 2
ABSTRACT 
 Botulinum neurotoxins (BoNT) are divided into 7 toxinotypes based on their 
immunological properties and each toxinotype contains several subtypes according to their 
amino acid sequences. Here, we designed a spectrometry method able to identify BoNT/A 
subtypes in complex matrices including crude culture supernatants, food and environmental 
samples. Peptides from BoNT light chain (L) specific of the subtypes BoNT/A1 to A3 and 
BoNT/A5 to A8 were identified. The method consists of an immunocapture step with 
antibodies specific of BoNT/A L chains followed by liquid chromatography/triple quadrupole 
tandem mass spectrometry (LC-QqQ-MS). BoNT/A subtypes were correctly identified in 
culture supernatants and in tape water or orange juice samples with a limit of detection of 20 
to 150 mouse lethal doses (MLD) and to a lower extent in serum samples. 
 
INTRODUCTION 
 Botulinum neurotoxins (BoNTs) are the most potent toxins and are responsible for a 
severe paralytic disease, botulism, in man and animals. Most often, botulism occurs 
subsequently to the ingestion of food contaminated with Clostridium botulinum and 
containing preformed BoNT. The toxin is absorbed from the intestine, and reaches the 
neuromuscular junction via the blood or lymph circulation and the interstitial fluid. BoNTs act 
at the neuromuscular junction in inhibiting the evoked release of acetylcholine, thus leading to 
paralytic symptoms including blurred vision, ptosis, dry mouth, difficulty in swallowing, then 
descending flaccid paralysis of voluntary muscles and respiratory insufficiency [1-3].  
BoNTs are divided into 7 toxinotypes (A to G) based on their immunological 
properties using the mouse biological test and specific neutralizing antisera [4,5]. A new 
subtype, called H, has been reported and waits for further characterization [6]. BoNT genes 
have been sequenced from a large number of strains and sequence comparison has permitted 
to identify sequence variations in each toxinotype. Thereby, botulinum toxinotypes are 
divided into subtypes [7]. Five BoNT/A subtypes (A1 – A5) have been identified and recently 
three additional subtypes (A6 to A8) are under characterization [8,9] (GenBank ACW83608, 
JQ954969, KF667385, respectively). Signification of sequence diversity in each toxinotype is 
not yet well known, but could be important in diagnostic tests and development of therapeutic 
agents such as those based on immunotherapy. Indeed, BoNT/A1 and BoNT/A2, which 
differs by 10% at the amino acid sequence level, show large differences in monoclonal 
antibody-binding affinity. Among six monoclonal antibodies, which bind to BoNT/A1 with 
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high affinity, three show a marked decrease in binding affinity (500 to more than 1000 fold) 
to BoNT/A2. Only combinations of monoclonal antibodies, which tightly bind to toxin 
subtype, potently neutralize the corresponding toxin in vivo. Association of the three 
monoclonal antibodies with high affinity binding to subtypes A1 and A2, completely 
neutralizes A1 or A2 toxin, while replacement of two from three monoclonal antibodies by 
two having a low binding affinity to BoNT/A2 induces a decrease in BoNT/A2 neutralization 
(50 fold less) [10]. Sequence variation among subtypes might also impact the toxin activity 
and subsequently the course of the disease. The enzymatic site of BoNT/A3 and BoNT/A4 
light (L) chain is conserved, but non-conservative mutations are observed in domains 
involved in substrate (SNAP-25) recognition [11]. Therefore, L chains from subtypes A3 and 
A4 show different catalytic properties with the substrate SNAP25 compared to L chain from 
subtypes A1 and A2, which show the same catalytic activity, although all L chain isoforms 
bind SNAP25 with similar affinity. L chain from subtype A4 and to a lower extent from 
subtype A3, cleaves less efficiently SNAP25 than L chain subtype A1 (2 and 23 fold less, 
respectively) [12,13]. BoNT/A1 to A5 exhibit distinct in vitro catalytic activity as well as 
different biological activity in neuronal cell and mouse models [14]. BoNT/A2 enters 
neuronal cells faster than BoNT/A1 and it is more potent [15]. In addition, BoNT/A2 is a 
more potent inhibitor of neurotransmission at the neuromuscular junction [16]. However, both 
toxins have comparable duration of action [17]. 
Subtype identification is usually performed via PCR amplification of bont genes and 
subsequent DNA sequencing [7,18]. This method requires the presence of the toxigenic strain 
in the samples and optimally strain isolation and DNA extraction. However, certain samples 
might contain BoNT in the absence of the bacterium yielding impossible the use of traditional 
DNA-based methods. Mass spectrometry (MS) methods have been developed to detect active 
BoNTs through peptide identification from substrate cleavage (Endopep-MS) (review in 
[19]). Endopep-MS is a sensitive method to detect BoNT types, but it cannot identify the 
toxin subtypes, since all the subtypes of each type recognize the same cleavage site. Tryptic 
digestion of the toxin itself and analysis of tryptic peptides by MS might allow subtype 
determination. Thereby, BoNT/A1 and BoNT/A2 have been identified in spiked milk samples 
based on differential peptides between the two subtypes [20]. A similar approach has been 
described to differentiate the subtypes of BoNT/B [21]. A multiple enzyme and sequential in-
gel digestion approach (MESID) has been proposed for BoNT subtyping. The multiple 
proteolytic enzymes used in this method facilitate near-complete sequence coverage of all the 
seven BoNT toxinotypes [22]. 
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Here, we report a liquid chromatography/triple quadrupole tandem mass spectrometry 
with multiple reaction monitoring method (LC-QqQ-MS) for subtyping BoNT/A in culture 
supernatants or biological and food samples. 
 
EXPERIMENTAL 
Safety considerations 
BoNTs have been handled with strict respect to safety rules for the handling of toxic 
substances. 
 
Materials and chemicals 
C. botulinum strains used in this study are listed in Table 1. C. botulinum strains were 
grown in trypticase-glucose-yeast extract medium in anaerobic conditions for 4 days. Culture 
supernatants were stored at -80°C until use. The presence of toxin in the supernatant was first 
detected by immune-chromatographic test (BTA Gold Assay. NBC-Sys, France) and the toxin 
activity (MDL100.ml
-1) was then tested by mousse bioassay as previously described [23]. All 
the peptides used were provided by Proteogenix (France) with purity greater than 95%. The 
lyophilized peptides were suspended in H2O/HPLC-grade acetonitrile (ACN) 50/50 at a 
concentration of 1 mg.ml-1 and stored at -20°C. A rabbit anti-peptides polyclonal antibody 
(anti-peptides PAb) was specifically generated by Proteogenix for the immune-magnetic 
separation. Two peptides: Q67-K84 (QVPVSYDSTYLSTYLSTDNEK) and D49-K66 
(DTFTNPEEGDLNPPPEAK) from light chain (Lc) were selected for the immunization. The 
peptide Q67-K84 is common to the subtypes A1, A2, A3, A5, A6, A7 and A8. The peptide 
D49-K66 is present in all subtypes but shows one mutation in the A7 subtype (I50 to T) and 
in the A8 subtype (K55 to E). Despite these mutations, the two peptides were recognized by 
the anti-peptides PAb. The reactivity of the anti- peptides PAb with the BoNT/A1, /A2, /A3, 
/A5, /A7 and /A8 was checked by Elisa procedure (data not shown). The absence of cross-
reactivity against BoNT/A heavy chain (Hc), BoNT/B and BoNT/E was tested by Western-
Blot (data not shown). 
 The food and environmental samples were from local source (local tape water), local 
grocery (orange juice), and French Defense Health Service (human serum). 
 
Animals and ethics statement 
Approval of Ethic Committee of DGA Maîtrise NRBC was obtained. BALB/C mice 
(female, 4 weeks old) were purchased from Charles River. The animals were fed with 
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standard diet and water ad libidum. The mice severely injured were euthanized. 
Determination of mouse lethal dose (MLD100) was performed as previously described [24]. 
Briefly, 0.5 ml of serial 10- fold and then 2-fold dilutions of samples in phosphate buffer (50 
mM, pH 6.3) containing 0.2% gelatin were injected intraperitoneally (3 mice per dilution). 
The mice were observed up to 4 days. 
 
Preparation of anti-peptides PAb coated magnetic beads 
Protein G-conjugated magnetic beads (Dynabeads Protein G, Novex) (250 µl) were 
transferred in a 2 ml Eppendorf low binding micro centrifuge tube and were washed three 
times with 500 µl of PBST (Phosphate Buffer Salt, 0.1 % Tween 20). After removing the final 
solution wash, the beads were suspended in 500 µl of PBST containing 100 µg. ml-1 anti-
peptides PAb. The mixture was incubated for 30 min with rotation at laboratory temperature. 
The beads were washed three times with 1 ml of PBS containing 0.15 M NaCl. Antibodies 
were cross-linked to the beads by incubating, for 30 min with rotation at laboratory 
temperature, in 1250 µl of PBS containing 0.15 M NaCl and 5 mM BS3 (crosslinking 
reagent). 65 µl of Tris/HCl 1 M pH 7.5 were added for quenching the cross-linking reaction. 
After incubation for 15 min at laboratory temperature with rotation, the beads were washed 
three times with 1 ml of PBST and resuspended in 250 µl of PBST. They were stored at 4°C 
for as long as 3 weeks. 
 
In-gel digestion 
Each culture supernatant of distinct C. botulinum strains from BoNT subtype was 
precipitated with 60 % of ammonium sulfate. After precipitation, the pellet was dissolved in 
50 mM sodium citrate buffer pH 5.5 and dialyzed overnight at 4°C against the same buffer. 
The dialyzed sample was fractionated via molecular size chromatography [25] using an 
AKTÄ system and an S300 column (HiPrep 26/60 Sephacryl S-300 HR - GE Healthcare Bio-
Sciences). For each subtype, the relevant fractions were pooled and considered as pre-purified 
complexes.  The amount of proteins on pre-purified complexes was determined by the Bio-
Rad protein assay with Bovine IgG as standard protein. 1 to 2 µg of each pre-purified 
complex for each BoNT subtype were run on a SDS-PAGE. After migration, gels were fixed 
and stained with Coomassie staining solution (Bio-Rad, Marnes la Coquette, France). Based 
on protein size, gel regions containing protein to identify were excised and cut into small 
pieces. Gel pieces were destained by washing cycles in water and acetonitrile for 10 min. 
After destaining, gel pieces were dried by vacuum centrifugation and reduced with DTT 
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10mM in 50 mM ammonium carbonate buffer and alkylated with iodoacetamide 55mM in 50 
mM ammonium carbonate buffer. Gel pieces were washed again with 50 mM ammonium 
carbonate buffer and dehydrated in 100% acetonitrile (ACN) before trypsin digestion (15 
µg.ml-1) at 4°C during 45 min and 2 hours at 37°C. Tryptic peptides were extracted from the 
gel in three successive steps (15 min each), using 2 cycles of 5% formic acid, and then 100% 
ACN extraction solutions. After drying by vacuum centrifugation, tryptic peptides were 
resuspended in 20 µl of 1% TFA before LC-ESI-MS/MS analysis.  
 
Immunocapture enrichment and trypsin digestion 
Culture supernatants or samples, crude or diluted in PBS, in a volume of 500 µl were 
treated with beta-mercaptoethanol (35 µl of 14 M stock solution) for 10 min at 95 °C in a dry 
heating block. After cooling at room temperature, each sample was mixed with 100 µl of 
PAb-coated magnetic beads in an Eppendorf low binding microcentrifuge tube. The mixture 
was incubated for 120 min at laboratory temperature with rotation. The beads were then 
recovered using a magnetic particle concentrator and washed three times with 1 ml of Hepes 
buffer (pH 7.6, 50 mM). The beads were then suspended in 100 µl of 100 mM ammonium 
carbonate buffer (pH 8.5) and incubated for 10 min at 95°C. 15 µl of 100 µg.ml-1 aqueous 
trypsin solution (sequencing grade modified trypsin, Promega) was added and the enzymatic 
digestion was carried out at 38°C for 120 min. After digestion, the magnetic beads were 
removed and 2 µl of analytical grade formic acid (FA) was added. The solution was vacuum-
dried and resuspended in 50 µl of H2O/ ACN/FA 93/5/2 before the LC-QqQ-MS anlysis.. 
LC-ESI-MS/MS analysis 
ESI-LC-MS/MS analysis was performed on an Esquire 6000 mass spectrometer 
(Bruker Daltonics, Bremen, Germany) connected with an Ultimate 3000 high performance 
liquid chromatograph (Dionex Corp., Sunnyvale, CA). The protein digest (10 µL) was 
injected on a 0.3 × 150 mm PepMap100 capillary column, particle size 5 µm, 100 Å pore size 
(LC Packings, Amsterdam, The Netherlands). Samples were eluted using a gradient starting 
with a linear increase from 5 to 10% acetonitrile over 4 min, followed by an increase from 10 
to 80% acetonitrile over 42 min with 0.2% acid formic throughout as additives. The data 
acquisition was performed using the data-dependent mode where the three highest-intensity 
precursors in an MS1 survey scan were selected for collision-induced dissociation. The 
resulting MS/MS data were searched for protein candidates with a database search against 
NCBInr database using MASCOT software (Matrix version 2.2.07, Sciences, London, U.K.). 
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The mass tolerance of precursor ions and fragment ions was 0.5 Da. Resulting peptides were 
filtered with a significance threshold of p < 0.05. 
 
LC-QqQ-MS analysis 
The HPLC system used for this analysis was an Ultimate 3000 RSLC equipped with a 
degasser, a binary pump, an auto-injector and a column oven (Thermo Scientific) coupled to a 
TSQ Quantiva electrospray ionization triple quadrupole mass spectrometer (Thermo 
Scientific). Chromatographic separations were performed on Zorbax SB-C18 2.1 × 150 mm, 
3.5 µm, 80Å pore size (Agilent) using 0.2% (v/v) formic acid as eluent A and acetonitrile 
with 0.2% formic acid as eluent B with a flow rate of 200 µL/min at 25°C. Samples (10 µl) 
were analyzed in a gradient mode: 5% eluent B (0–2 min) and 50% B (30 min). The mass 
spectrometer ESI source was operated in positive ionization mode. The following conditions 
were applied: spray voltage, 4000 V; sheath gas, 50 Arb; aux gas, 10 Arb; sweep gas, 5 Arb; 
ion transfer tube temp, 325°C; vaporizer temp, 275°C; CID gas, argon, 2 mTorr.  
 
Food and biological samples 
 Food and human serum samples were artificially spiked with culture supernatant of 
each C. botulinum A subtype, and 0.5 ml of each sample were treated as above described for 
the culture supernatants except that the serum samples were not heated. Serial 10 fold 
dilutions of each sample were tested by mouse bioassay and by immunocapture/ LC-QqQ-MS 
method. 
 
RESULTS 
Selection of specific peptides for botulinum toxin A subtypes detection 
MS-based analysis can distinguish proteins on the basis of amino acid sequence. 
BoNT/A1 to BoNT/A8 subtypes share 84.5 to 97.2 % identity at the amino acid level (Table 
2). We first identified the trypsic cleavage sites on the sequences of the L chain (amino acids 
1 to 449) of each BoNT/A subtype and we then analyzed all the subsequent peptides for their 
specificity versus the other BoNT/A subtypes by Blast. Thereby, 26 peptides of each BoNT/A 
subtypes were analyzed in silico. Two to 12 unique peptides for each BoNT/A subtype were 
synthesized and analyzed in MS (Table 3). For each subtype, two specific peptides yielding 
the highest MS signals were selected. One peptide was common to both BoNT/A2 and 
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BoNT/A8, and two other to BoNT/A1 and BoNT/A6. Moreover, two additional peptides 
which were conserved in all BoNT/A subtypes were also selected (Table 4).  
To validate the selection of these peptides for the identification of BoNT/A subtypes, 
BoNT preparations of each subtype (1 to 2 µg) were run on a SDS-PAGE and the bands 
containing the L chain were cut out of the gel. After in gel trypsin digestion, the peptides were 
extracted and analyzed with LC-ESI-MS/MS (data not shown). BoNT/A4 and BoNT/A6 were 
not included in this study due to the difficulty to obtain BoNT/A4 preparations containing 
sufficient amounts of toxin and to the fact that BoNT/A6 (strain CDC41370) was not 
available in our collection.  
 
Identification of BoNT/A subtype in culture supernatants 
To identify BoNT/A subtype in a complex environment like culture supernatant, we 
used an immunocapture step. For that purpose, magnetic beads were coated with antibodies 
raised against two synthetic peptides conserved in BoNT/A light chain subtypes as described 
in the Experimental part. Culture supernatant samples (500 µl) were reduced by addition of 
betamercaptoethanol to allow the separation of L and H chains and were then incubated with 
coated magnetic beads. After washing, the bound material was digested by trypsin in-situ, 
dried, and analyzed by LC-MS/MS. An example of conserved peptide detection by LC-
MS/MS in culture supernatants of representative strains of each BoNT/A subtype is shown in 
Fig. 1. Clostridium sporogenes which is closely related to C. botulinum A strains showed no 
detectable peptide corresponding to L chain fragment. Fig. 2 shows identification of 
BoNT/A2 through detection of the specific subtype peptide (DVASTLNK) detection by LC-
MS/MS in C. botulinum culture supernatants. The global results of peptide detection in C. 
botulinum culture supernatants are listed in Table 5. The selected conserved peptides were 
detected in all the C. botulinum culture supernatants tested, whereas the selected specific 
subtype peptides were only identified in the corresponding C. botulinum subtype culture 
supernatants. However, the I376-K387 peptide was detected in both C. botulinum A2 and A8 
subtype culture supernatants, in contrast to the D292-K299 peptide which was only found in 
C. botulinum A2 strains (Table 5). 
 
Sensitivity 
The limit of detection (LOD) of the LC-QqQ-MS method was estimated by using 
serial dilutions of C. botulinum culture supernatants. LOD corresponded to the highest 
dilution giving a signal with a signal-to-noise ratio of 3. The results with representative C. 
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botulinum culture supernatant subtypes and expressed in equivalent MLD100 which have 
been determined by the mouse bioassay, are shown in Table 6. The MS methodology could 
detect BoNT ranging from 20 to 140 MLD/0.5 ml according to the subtype. 
 
Identification of BoNT/A subtype in different matrices 
 In order to validate the LC-QqQ-MS methodology with biological, food or 
environmental samples, LOD was determined in various representative matrices (tape water, 
orange juice, human serum) spiked with the distinct BoNT/A subtypes. As shown in Table 7, 
the BoNT/A subtypes A1 to A8 were successfully identified in all the different samples. The 
highest LOD values were obtained with tape water and orange juice and were comparable to 
those obtained with culture supernatants (Table 6), whereas the detection was slightly lower 
(4 to 10 fold less) in human serum. 
 
DISCUSSION 
 Detection of BoNT in biological samples and food is critical for early diagnosis of 
botulism and to apply an efficient treatment of the disease. Investigation of BoNT in food or 
environmental samples is also essential for identifying the source of contamination and 
preventing outbreak extension of botulism. Typing and subtyping are important to estimate 
the severity of the disease and to adapt the appropriate treatment notably the specificity of the 
antisera. MS is a rapid and powerful method to identify proteins. Here, we show that a LC-
QqQ-MS method coupled to an immunopurification step allows identification of BoNT/A 
type and subtypes from complex samples. The method based on L chain peptides specific of 
BoNT/A subtypes A1 to A8 yielded unambiguous identification of the subtypes. A previous 
MS approach has been designed to differentiate BoNT/A1 and BoNT/A2 [20]. Identification 
of BoNT types A1 to G was achieved by using multiple enzyme digestion in gel and 
subsequent LC-QqQ-MS analysis. This method is predicted to identify the subtypes but has 
not yet been validated [22]. Our procedure efficiently discriminated the distinct BoNT/A 
subtypes. One important advantage is that complex samples can be used. Subtyping was 
efficiently performed with crude culture supernatants. An additional advantage is that this 
method of subtyping is performed in one step without the need of further techniques or 
reagents to address the subtyping. However, this method would be tested with complex and 
naturally contaminated samples like food or stools. LOD of the proposed method (20 to 140 
equivalents MLD in 0.5 ml) is in the range of the minimal toxin concentrations found in food. 
The sensitivity of the method could be increased by using a greater sample volume. Using 
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artificially spiked samples representative of food, environmental and biological samples, the 
LC-QqQ-MS method allowed the identification of all the BoNT/A subtypes tested. LOD 
varied with the matrix, with the lowest values in serum samples. Albeit the proposed method 
is not sensitive enough to detect limited BoNT amounts, it is appropriate for contaminated 
environmental or food samples which usually contain significant BoNT concentrations (100 
MLD/g and more). The advantage of the LC-QqQ-MS approach is to allow subtype 
identification in the absence of viable neurotoxin producing bacteria or available DNA in 
samples to perform a genetic subtyping. Further developments are still required for 
application with biological samples. It is noteworthy that this methodology might be updated 
to identify new subtypes that will be evidenced, by selecting additional specific peptides on 
light and/or heavy chains. 
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LEGENDS TO FIGURES 
 
Figure 1. Example of detection of a conserved peptide in culture supernatants from 
representative C. botulinum A subtypes. Ion chromatograms of SRM transition 565.8/684.4 
(LYGIAINPNR peptide) from BoNT/A1 (strain Hall), BoNT/A2 (strain 9336), BoNT/A3 
(strain Loch Maree), BoNT/A5 (strain 126.07), BoNT/A7 (strain 148.08), and BoNT/A8 
(strain 217.12) supernatants. Clostridium sporogenes (strain 261.05) supernatant was used as 
negative control. The expected retention time is 15.7 min. 
 
Figure 2. Example of detection BoNT/A2 in culture supernatants from representative C. 
botulinum A subtypes. Ion chromatograms of SRM transition 424.2/215.1 (DVASTLNK 
peptide) from BoNT/A1 (strain Hall), BoNT/A2 (strain 9336), BoNT/A3 (strain Loch Maree), 
BoNT/A5 (strain 126.07), BoNT/A7 (strain 148.08), and BoNT/A8 (strain 217.12) 
supernatants. Clostridium sporogenes (strain 261.05) supernatant was used as negative 
control. The expected retention time is 10.1 min.  
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Neurotoxin 
gene cluster 
Strain 
Lethal activity 
(MLD100/ml) 
ha-bont/A1 Hall 2.10
4
 
ha-bont/A1 Legroux 1.10
5
 
orfX-bont/A1(B) NCTC2916 1.10
5
 
orfX-bont/A1 200.04 2.10
5
 
orfX-bont/A2 
136.06 2.10
4
 
133.06 2.10
4
 
9336 2.10
5
 
181.02 2.10
5
 
1618 2.10
5
 
orfX-bont/A3 Loch Maree 2.10
3
 
ha-bont/A5 126.07 2.10
4
 
orfX-bont/A7 148.08 2.10
4
 
orfX-bont/A8 217.12 1.6.10
4
 
 
 
Table 1. List of C. botulinum strains used in this study, their neurotoxin gene cluster, and 
mouse lethal activity of culture supernatant as tested with mouse bioassay.  
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 A2 A3 A4 A5 A6 A7 A8 
A1 90.0 84.9 89.4 97.2 95.7 93.8 93.4 
A2  93.4 88.4 90.5 91.7 89.8 93.5 
A3   84.5 85.4 86.5 85.1 88.0 
A4    87.6 87.9 86.9 89.1 
A5     95.9 94.4 93.7 
A6      93.0 93.1 
A7       91.4 
 
 
 
Table 2. Amino acid sequence identity (%) of BoNT/A subtypes. Amino acid sequences from 
representative strains are: BoNT/A1 from strain Hall (YP_001386738.1); BoNT/A2 from 
strain Kyoto (CAA51824.1); BoNT/A3 from strain Loch Maree (YP_0017157303.1); 
BoNT/A4 from strain BA857 (YP_002860313.1); BoNT/A5 from strain IBCA94-0216 
(ACT33194.1); BoNT/A6 from strain CDC 41370 (ACW83608.1); BoNT/A7 from strain 
148.08 (AFV13854.1); BoNT/A8 from strain 217.12 (AHA83316.1). 
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Specificity Tryptic digest  fragment peptide sequence  
Conserved
a 
I24-K34 IPNAGQMQPVK  
Conserved
a 
Q67-K84 QVPVSYYDSTYLSTDNEK  
Conserved
a 
G114-K128 GIPFWGGSTIDTELK  
Conserved
b 
N178-R187 NGYGSTQYIR  
Conserved
a 
L232-R241 LYGIAINPNR  
Conserved
b 
N418-K427, N414-K423 for BoNT/A3 NFTGLFEFYK  
BoNT/A1 and A6
c 
S167-R177 SFGHEVLNLTR  
BoNT/A1 and A6
c 
V382-R393 VNYTIYDGFNLR  
BoNT/A2 and A8
d 
F213-R231 FATDPAVTLAHELIHAEHR   
BoNT/A2 D292-K299 DVASTLNK  
BoNT/A2 and A7
e 
S302-K314 SIIGTTASLQYMK  
BoNT/A2 M344-K359 MLTEIYTEDNFVNFFK  
BoNT/A2 and A8
c 
I376-K387 INIVPDENYTIK  
BoNT/A2 G394-R411 GANLSTNFNGQNTEINSR  
BoNT/A3 I38-R48 IHEGVWVIPER   
BoNT/A3 I98-R105 IYSTGLGR  
BoNT/A3 M106-K113 MLLSFIVK  
BoNT/A3 V129-R145 VIDTNCINVIEPGGSYR  
BoNT/A3 S146-K166 SEELNLVITGPSADIIQFECK  
BoNT/A3 S167-R177 SFGHDVFNLTR  
BoNT/A3 T247-R264 TNAYYEMSGLEVSFEELR  
BoNT/A3 T265-R280 TFGGNDTNFIDSLWQK  
BoNT/A3 D285-R295 DAYDNLQNIAR  
BoNT/A3 T302-K314 TIVGTTTPLQYMK  
BoNT/A3 Y321-K330 YFLSEDASGK   
BoNT/A3 G348-K359 GFTELEFVNPFK  
BoNT/A5 I98-R105 IYSTELGR   
BoNT/A5 T265-K272 TFGEHDAK  
BoNT/A5 I376-R393 INIVPEVNYTIYDGFNLR   
BoNT/A6 N394-K415 NTNLAANFNGQNTEINNMNFAK  
BoNT/A7 D49-K66 DIFTNPEEGDLNPPPEAK  
BoNT/A7 S146-K166 SEELNLVIIGPSADIINFECK  
BoNT/A7 F213-R231 FAIDPAVTLAHELIHAGHR  
BoNT/A7 E292-K299 EVASILNK   
BoNT/A7 M376-R393 MNIVPEVNYTIYDGFNLR   
BoNT/A8 D12-K23 DTVNGVDIAYIK   
BoNT/A8 D49-K55 DTFTNPK   
BoNT/A8 E56-K66 EGDLNPPPEAK   
BoNT/A8 T265-K272 TFGGHNAK  
BoNT/A8 N394-R411 NTNLAANFNGQNTEINSR   
 
 
Table 3. Proteolytic peptides (peptide size between 7 and 25 amino acids) of BoNT/A1 to A8 
light chains. 
a Peptides conserved in BoNT/A1-/A3 and BoNT/A5-/A8 light chains. 
b Peptides conserved in BoNT/A1 to A8 light chains 
c Peptides common to BoNT/A2 and BoNT/A6 light chains 
d Peptides common to BoNT/A2 and BoNT/A8 light chains 
e Peptides common to BoNT/A2 and BoNT/A7 light chains 
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Specificity 
Tryptic digest 
fragment 
Proteotypic peptide 
sequence 
SRM transitions 
Retention 
time (min.) 
Precursor 
 (m/z) 
Product  
(m/z) 
Conserved G114-K128 GIPFWGGSTIDTELK 810.9 
601.3 
20.5 725.9 
1020.5 
Conserved L232-R241 LYGIAINPNR 565.8 
334.2 
15.7 684.4 
854.5 
BoNT/A1 S167-R177 SFGHEVLNLTR 424.9 
389.3 
15.3 503.3 
657.3 
BoNT/A1 V382-R393 VNYTIYDGFNLR 737.9 
214.1 
19.0 884.4 
997.5 
BoNT/A2 D292-K299 DVASTLNK 424.2 
187.1 
10.1 215.1 
633.4 
BoNT/A2 and A8 I376-K387 INIVPDENYTIK 709.9 
228.1 
16.3 341.2 
979.5 
BoNT/A3 S167-R177 SFGHDVFNLTR 431.6 
276.2 
16.4 389.3 
503.3 
BoNT/A3 G348-K359 GFTELEFVNPFK 714.4 
391.2 
22.0 505.3 
880.5 
BoNTA5 I98-R105 IYSTELGR 469.8 
277.2 
12.1 662.4 
825.4 
BoNTA5 I376-R393 INIVPEVNYTIYDGFNLR 714.0 
440.3 
22.6 721.4 
884.4 
BoNTA7 E292-K299 EVASILNK 437.3 
487.3 
13.1 574.4 
645.4 
BoNTA7 M376-R393 MNIVPEVNYTIYDGFNLR 720.0 
359.17 
22.0 458.2 
884.4 
BoNTA8 E56-K66 EGDLNPPPEAK 583.8 
541.3 
10.5 638.4 
752.4 
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Table 4. MS analysis of BoNT/A light chain peptides. Results of MS analysis of synthetic 
peptides specific of each BoNT/A subtype. 3 transitions for each analysis, n=3. 
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Table 5. Results of peptide detection by LC-MS/MS in C. botulinum culture supernatants. n=3. 
 
 L232-R241 
( conserved) 
G114-K128 
(conserved) 
S167-
R177 
(BoNT/A1) 
V382-
R393 
(BoNT/A1) 
D292-
K299 
(BoNT/A2) 
 
I376-K387 
(BoNT/A2-
/A8) 
 
S167-
R177 
(BoNT/A3) 
G348-
K359 
(BoNT/A3) 
I98-R105 
(BoNT/A5) 
I376-R393 
(BoNT/A5) 
E292-K299 
(BoNT/A7) 
M376-
R393 
(BoNT/A7) 
E56-K66 
(BoNT/A8) 
Hall - BoNT/A1 + + + + - - - - - - - - - 
Legroux - BoNT/A1 + + + + - - - - - - - - - 
NCTC2916 -  BoNT/A1 + + + + - - - - - - - - - 
200.04 - BoNT/A1 + + + + - - - - - - - - - 
136.06 -  BoNT/A2 + + - - + + - - - - - - - 
133.06 - BoNT/A2 + + - - + + - - - - - - - 
9336- BoNT/A2 + + - - + + - - - - - - - 
181.02- BoNT/A2 + + - - + + - - - - - - - 
1618- BoNT/A2 + + - - + + - - - - - - - 
Loch Maree- BoNT/A3 + + - - - - + + - - - - - 
126.07- BoNT/A5 + + - - - - - - + + - - - 
148.08- BoNT/A7 + + - - - - - - - - + + - 
217.12- BoNT/A8 + + - - - + - - - - - - + 
Strain  
Peptide 
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C. botulinum A subtype Detected peptide LOD (MLD100) 
Hall (A1) S167-R177 110 ± 16 
9336 (A2) D292-K299 30 ± 4.5 
Loch Maree (A3) S167-R177 50 ± 7.5 
126.07 (A5) I98-R105 20 ± 3 
148.08 (A7) M376-R393 140 ± 21 
271.12 (A8) E56-K66 50 ± 7 
 
 
 
Table 6.  Estimated limit of detection (LOD). LOD is expressed in equivalent MLD100/0.5 ml. 
Signal to noise ratio of 3. Results are mean values ± SD. n=3. 
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Matrices Hall (A1) 9336 (A2) 
Loch Maree 
(A3) 
126.07 (A5) 148.08 (A7) 271.12 (A8) 
Tape Water 70 20 50 15 110 50 
Orange juice 110 50 70 20 150 60 
Human serum 300 200 250 100 500 300 
 
Table 7.  Estimated limit of detection (LOD expressed in equivalent MLD100/0.5 ml) in 
various samples. Signal to noise ratio of 3. n=3. 
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Example of detection of a conserved peptide in culture supernatants from representative C. botulinum A 
subtypes. Ion chromatograms of SRM transition 565.8/684.4 (LYGIAINPNR peptide) from BoNT/A1 (strain 
Hall), BoNT/A2 (strain 9336), BoNT/A3 (strain Loch Maree), BoNT/A5 (strain 126.07), BoNT/A7 (strain 
148.08), and BoNT/A8 (strain 217.12) supernatants. Clostridium sporogenes (strain 261.05) supernatant 
was used as negative control. The expected retention time is 15.7 min.  
529x764mm (72 x 72 DPI)  
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Example of detection BoNT/A2 in culture supernatants from representative C. botulinum A subtypes. Ion 
chromatograms of SRM transition 424.2/215.1 (DVASTLNK peptide) from BoNT/A1 (strain Hall), BoNT/A2 
(strain 9336), BoNT/A3 (strain Loch Maree), BoNT/A5 (strain 126.07), BoNT/A7 (strain 148.08), and 
BoNT/A8 (strain 217.12) supernatants. Clostridium sporogenes (strain 261.05) supernatant was used as 
negative control. The expected retention time is 10.1 min.  
529x764mm (72 x 72 DPI)  
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